Skip to content

Resection and reconstruction of pelvic organs for refractory rectal cancer: a single-center retrospective study

Resection and reconstruction of pelvic organs for refractory rectal cancer: a single-center retrospective study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400085367
Enrollment
Unknown
Registered
2024-06-06
Start date
2024-06-10
Completion date
Unknown
Last updated
2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rectal cancer

Interventions

PE for patients with Refractory rectal cancer (They were divided into two groups according to preoperative metastasi):NA

Sponsors

Department of Gastrointestinal Surgery, Peking University Shougang Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. 18-80 years old patients with complete case data; 2. preoperative imaging of rectal cancer that met the requirements for the American Joint Committee on Cancer (AJCC) stage T4b, 3. preoperative imaging showing tumor invasion of one or more organs adjacent to the rectum, 4. pathological confirmation of primary (recurrent) bowel cancer, 5. patients deemed suitable for local R0 resection based on MDT discussion, and 6. critically ill patients with the above conditions accompanied by an Eastern Cooperative Oncology Group (ECOG) score of =3 or American Society of Anesthesiologists (ASA) score of =3, with insufficiency of a major organ (e.g., the heart, brain, lung) but deemed fit for surgery based on MDT evaluation.

Exclusion criteria

Exclusion criteria: 1. patients with extensively metastasized or recurrent rectal cancer, 2. patients with rapidly progressing bowel cancer, 3. patients with multiple organ insufficiencies and deemed unfit for surgery based on MDT evaluation, 4. patients with concurrent primary tumors in other organs, 5. patients who refused MDT evaluation for preoperative neoadjuvant therapy, and 7. patients with lesions invading the sacrum 1 and 2.

Design outcomes

Primary

MeasureTime frame
OS;

Secondary

MeasureTime frame
R0 resection rate;

Countries

China

Contacts

Public ContactQingkun Gao

Department of Gastrointestinal Surgery, Peking University Shougang Hospital

gqk333@163.com+86 152 0164 7621

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026